Arizona · G0483

Drug Test(s), Definitive, Utilizing (1) Drug Identification Methods Able To Identify Individual Drugs And Distinguish Between Structural Isomers (but Not Necessarily Stereoisomers), Including, But Not Limited To Gc/ms (any Type, Single Or Tandem) And Lc/ms in Arizona

Arizona Medicare Avg
$241.22
0% above national avg
National Medicare Avg
$240.59
All states combined
Billed Charge (AZ)
$592.91
What providers submit
Est. Commercial (AZ)
$549.99
National avg: $538.93
Est. Cash / Self-Pay (AZ)
$343.97
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

17.9K
Services in AZ
34
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Arizona

Provider Medicare Services
Genetic Technological Innovations,... $241.98 6.1K
Pico, Tristan MD $241.12 2.7K
Seth, Nikesh MD $238.22 1.9K
Saran, Craig $240.85 1.3K
Phoenix Toxicology & Lab Services $241.98 1.3K
Rubin, Mark M.D. $241.98 912
Smith, Dallas D.O. $241.98 742

Arizona Pricing in Context

In Arizona, CPT code G0483 (Drug Test(s), Definitive, Utilizing (1) Drug Identification Methods Able To Identify Individual Drugs And Distinguish Between Structural Isomers (but Not Necessarily Stereoisomers), Including, But Not Limited To Gc/ms (any Type, Single Or Tandem) And Lc/ms) carries an average Medicare payment of $241.22 — 0% above the national benchmark of $240.59. 34 providers across the state submitted claims for this procedure in 2023, performing 17.9K total services. Individual payments in AZ ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Arizona is $592.91, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Arizona sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Temporary Procedures procedures, the estimated commercial insurance price in Arizona lands near $549.99, with self-pay cash prices typically around $343.97. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Drug Test(s), Definitive, Utilizing (1) Drug Identification Methods Able To Identify Individual Drugs And Distinguish Between Structural Isomers (but Not Necessarily Stereoisomers), Including, But Not Limited To Gc/ms (any Type, Single Or Tandem) And Lc/ms cost in Arizona?

The average Medicare payment for Drug Test(s), Definitive, Utilizing (1) Drug Identification Methods Able To Identify Individual Drugs And Distinguish Between Structural Isomers (but Not Necessarily Stereoisomers), Including, But Not Limited To Gc/ms (any Type, Single Or Tandem) And Lc/ms in Arizona is $241.22, which is 0% above the national average of $240.59. Providers in AZ typically bill $592.91 for this procedure.

What does Drug Test(s), Definitive, Utilizing (1) Drug Identification Methods Able To Identify Individual Drugs And Distinguish Between Structural Isomers (but Not Necessarily Stereoisomers), Including, But Not Limited To Gc/ms (any Type, Single Or Tandem) And Lc/ms cost with insurance in Arizona?

With commercial insurance in Arizona, Drug Test(s), Definitive, Utilizing (1) Drug Identification Methods Able To Identify Individual Drugs And Distinguish Between Structural Isomers (but Not Necessarily Stereoisomers), Including, But Not Limited To Gc/ms (any Type, Single Or Tandem) And Lc/ms costs an estimated $549.99. Without insurance, the estimated cash price is $343.97. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Drug Test(s), Definitive, Utilizing (1) Drug Identification Methods Able To Identify Individual Drugs And Distinguish Between Structural Isomers (but Not Necessarily Stereoisomers), Including, But Not Limited To Gc/ms (any Type, Single Or Tandem) And Lc/ms in Arizona?

34 providers in Arizona billed Medicare for Drug Test(s), Definitive, Utilizing (1) Drug Identification Methods Able To Identify Individual Drugs And Distinguish Between Structural Isomers (but Not Necessarily Stereoisomers), Including, But Not Limited To Gc/ms (any Type, Single Or Tandem) And Lc/ms in 2023, performing 17.9K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Drug Test(s), Definitive, Utilizing (1) Drug Identification Methods Able To Identify Individual Drugs And Distinguish Between Structural Isomers (but Not Necessarily Stereoisomers), Including, But Not Limited To Gc/ms (any Type, Single Or Tandem) And Lc/ms cheaper in Arizona than the national average?

No — Drug Test(s), Definitive, Utilizing (1) Drug Identification Methods Able To Identify Individual Drugs And Distinguish Between Structural Isomers (but Not Necessarily Stereoisomers), Including, But Not Limited To Gc/ms (any Type, Single Or Tandem) And Lc/ms costs 0% above the national average in Arizona. The state average Medicare payment is $241.22 compared to $240.59 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial